Hours

Minutes

Seconds

-40%

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

Valuation: ARYx Therapeutics, Inc.

Market Cap	9.03M 7.87M 7.26M 6.83M 12.77M 851M 12.86M 86.34M 33.53M 420M 33.91M 33.19M 1.45B	P/E 2008	-1.76x	P/E 2009	-2.66x
Enterprise Value	11.41M 9.94M 9.16M 8.62M 16.12M 1.07B 16.23M 109M 42.33M 530M 42.81M 41.89M 1.84B	EV / Sales 2008	4,019,605x	EV / Sales 2009	-
Free-Float	100%	Yield 2008 *	-	Yield 2009	-

* Estimated data More valuation ratios

Chart: ARYx Therapeutics, Inc.

Timeframe

Style

Dynamic Chart

Press Releases: ARYx Therapeutics, Inc.

11-03-09	ARYX THER : ARYx Therapeutics Informed of Additional Delay by FDA and Begins Wind-Down of Operations	BU
10-12-23	ARYX THER : ARYx Therapeutics Clarifies Current Status of Operations	BU
10-12-21	ARYX THER : ARYx Therapeutics to Transfer to the NASDAQ Capital Market	BU
10-12-15	ARYX THER : ARYx Therapeutics Provides Update on Company Status	BU
10-11-15	ARYX THER : ARYx Therapeutics Reports Third Quarter Results	BU

More press releases

ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets Other stock markets 12:13:44 2025-08-11 EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

3 years	0		0
5 years	0		0.04
10 years	0		0.05

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARYX THERAPEUTICS, INC.	-.--%	-.--%	-	-	33
ARGENX SE	+0.89%	-1.81%	+62.60%	+113.66%	54.44B
WUXI APPTEC CO., LTD.	+4.60%	+5.82%	+56.35%	+43.04%	45.8B
BIONTECH SE	-1.44%	+1.51%	-12.94%	-19.24%	22.98B
INSMED INCORPORATED	-2.69%	-0.95%	-3.68%	+379.00%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	+2.94%	+24.02%	-35.05%	16.25B
GENMAB A/S	+1.06%	+1.39%	+17.08%	-37.87%	15.34B
EXELIXIS, INC.	-1.01%	-2.97%	+27.42%	+171.92%	13.05B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+5.43%	+21.37%	-	12.37B
PHARMAESSENTIA CORPORATION	+4.95%	+13.49%	+121.11%	+249.05%	12.47B
Average	+1.26%	+1.97%	+34.81%	+108.07%	21.35B
Weighted average by Cap.	+1.52%	+1.38%	+39.35%	+98.38%

	2008	2009
Net sales	19.72 17.19 15.84 14.9 27.88 1.86K 28.07 188.48 73.2 916.09 74.03 72.45 3.18K	-
Net income	-31.22M -27.2M -25.07M -23.58M -44.12M -2.94B -44.43M -298M -116M -1.45B -117M -115M -5.03B	-33.17M -28.9M -26.64M -25.06M -46.88M -3.13B -47.21M -317M -123M -1.54B -124M -122M -5.34B
Net Debt	-29.9 -26.06 -24.02 -22.59 -42.27 -2.82K -42.56 -285.77 -110.98 -1.39K -112.25 -109.84 -4.81K	2.37 2.07 1.9 1.79 3.35 223.46 3.37 22.66 8.8 110.12 8.9 8.71 381.69

ARYx Therapeutics, Inc. Stock

Stocks

ARYX

US0433871094

Biotechnology & Medical Research

Valuation: ARYx Therapeutics, Inc.

Chart: ARYx Therapeutics, Inc.

Press Releases: ARYx Therapeutics, Inc.

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile